Paradise Ultrasound Renal Denervation System Receives
Good Design Award 2026

October 15, 2026

Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) announces that the Paradise™ Ultrasound Renal Denervation (uRDN) system has received the Good Design Award 2026 from the Japan Institute of Design Promotion. The Paradise uRDN system is a catheter-based medical device used as an adjunctive treatment option for patients with resistant hypertension.*

According to the World Health Organization (WHO), the number of people with hypertension worldwide doubled from approximately 650 million in 1990 to 1.3 billion in 2019.¹ In Japan, an estimated 43 million people have hypertension, while about 24.5 million receive treatment, representing fewer than 60% of those affected.²

Hypertension remains a major public health challenge because it often presents few symptoms, but can lead to serious health risks if left uncontrolled, including stroke and heart attack. Some patients are unable to achieve adequate blood pressure control despite lifestyle modifications and antihypertensive medications. To address this medical need, Recor Medical, Inc., a U.S.-based subsidiary of Otsuka Medical Devices, developed the Paradise uRDN system as a new treatment option for resistant hypertension.

The Paradise uRDN system was recognized by the Good Design Award for addressing unmet needs in hypertension treatment and for its patient-centered design. The Paradise uRDN system was FDA-approved and launched in the U.S. in 2023, received manufacturing and marketing approval in Japan in August 2025, and has been commercially available under Japan's national health insurance system since March 2026.

As part of its efforts to raise awareness of resistant hypertension, Otsuka Medical Devices provides an educational website for patients and their families, offering information on the condition's definition, risks, and treatment options. The website is intended for people whose blood pressure remains difficult to control despite lifestyle modifications and medication.

Resistant Hypertension Educational Website (Available in Japanese only)
[Medical Reviewer]Kazuomi Kario, Professor of Cardiovascular Medicine at Jichi Medical University

* Resistant hypertension: Hypertension that remains above target despite the use of three antihypertensive medications of different classes, including a diuretic.

References
1 World Health Organization (WHO), "More than 700 million people with untreated hypertension".
2 The Japanese Society of Hypertension, "For the General Public". (Available in Japanese only)

About the Good Design Award
The Good Design Award is Japan's only comprehensive design evaluation and promotion mechanism, established in 1957. It recognizes a wide range of designs, including products, architecture, services, systems, and initiatives, whether tangible or intangible. The G Mark, awarded to recognized designs, is widely known in Japan as a symbol that promotes good design throughout society. The year 2026 marks the 70th edition of the award.
https://www.g-mark.org/en

About Otsuka Medical Devices
Otsuka Medical Devices engages in the global development and commercialization of medical devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).

About Recor Medical
Recor Medical, headquartered in Palo Alto, Calif., and a wholly owned subsidiary of Otsuka Medical Devices, is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise uRDN system is FDA-approved in the United States, is CE 2797 marked and approved for sale in markets where the CE 2797 mark is accepted, per approved indications for use, and received manufacturing and marketing approval in Japan. Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise uRDN system in patients with mild-to-moderate and resistant hypertension. In addition, Recor has begun the Global Paradise System ("GPS") Registry in the European Union and the UK, and has initiated the US GPS post-approval study in the United States.

Contacts
Inquiry form